What is Ilumya (tildrakizumab) for?
Buy Ilumya (tildrakizumab). Ilumya (tildrakizumab) is a treatment for adults with plaque psoriasis. It helps those who need injections, pills, or light therapy. It’s a single-dose syringe with 100 mg/mL tildrakizumab.
How does Ilumya (tildrakizumab) work?
tildrakizumab is a protein that blocks IL-23 cytokines. These cytokines cause inflammation. They are linked to diseases like psoriasis.
By stopping IL-23, tildrakizumab reduces inflammation.
Where has Ilumya (tildrakizumab) been approved?
Ilumya (tildrakizumab) was approved by:
- The Food and Drug Administration (FDA), USA on March 20, 2018.
- The European Medicines Agency (EMA), Europe on September 17, 2018 under the brand name Ilumetri.
It also got Orphan Drug designation for type 1 diabetes, Crohn’s disease, ulcerative colitis, and systemic lupus erythematosus.
It might be approved in other places too. If you’re unsure, contact our support team.
How is Ilumya (tildrakizumab) taken?
The standard dosage is:
- Starting dose: 100 mg at Weeks 0, 4
- Every twelve weeks (3 months) thereafter
For more details, see the official prescribing information in our references section.
Note: Please consult with your treating doctor for personalised dosing.
Are there any known adverse reactions or side effects of Ilumya (tildrakizumab)?
Common adverse reactions
The most common side effects include:
- upper respiratory infections
- Injection site reactions
- Diarrhea
Serious adverse reactions
The serious side effects include:
- Increased risk of infections (bacterial, fungal, and viral)
Use in a specific population
It’s not known if Ilumya (tildrakizumab) harms fetuses. It’s advised to avoid pregnancy and breastfeeding.